Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Evaluation of cytarabine consolidation dosing in older adult patients with Acute Myeloid Leukemia

Pooja Kumar, Deedra Nicolet, Tracelyn Freeman, Lexus Frazier, Allyson Waller, Megan Fleming, Michael Walker, Gregory Behbehani, James Blachly, Uma Borate, Nicole Grieselhuber, Shivani Handa, Jayanshu Jain, Karilyn Larkin, Meixiao Long, Ann-Kathrin Eisfeld, Alice Mims

Blood (2025) 146 (Supplement 1): 3408.

https://doi.org/10.1182/blood-2025-3408

Published: 2025

Journal Articles

Toxicity of reduced dose versus standard dose pegaspargase in adolescents and young adults with acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 3344.

https://doi.org/10.1182/blood-2025-3344

Published: 2025

Journal Articles

Trial in progress: A Phase I/II study to investigate the combination of LP-118, ponatinib, vincristine and dexamethasone (LPVd regimen) in relapsed/refractory T-ALL/lbl

Blood (2025) 146 (Supplement 1): 5136.

https://doi.org/10.1182/blood-2025-5136

Published: 2025

Journal Articles

A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination with Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

Uma Borate, Kaitlyn M. Dvorak-Kornaus, Qiuhong Zhao, Roland B. Walter, Rachel J. Cook, Jennifer N. Saultz, Ronan T. Swords, Nicole R. Grieselhuber, Alice Mims, Karilyn T. Larkin, Kieran D Sahasrabudhe, James S. Blachly, Gregory K Behbehani, Ann-Kathrin Eisfeld, Meixiao Long, Andrew Srisuwananukorn, Kristin L Koenig

Blood (2024) 144 (Supplement 1): 4286.

https://doi.org/10.1182/blood-2024-210605

Published: 2024

Journal Articles

Real World Outcomes of Patients (Pts) with Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) or Therapy-Related AML (t-AML) Receiving Venetoclax-Based Therapies

Kelly Pugh, Michael C Walker, Deedra Nicolet, Victoria Klein, Krzysztof Mrózek, Gregory K Behbehani, James S. Blachly, Uma Borate, Nicole R. Grieselhuber, Kristin L Koenig, Karilyn T. Larkin, Meixiao Long, Andrew Srisuwananukorn, Ann-Kathrin Eisfeld, Alice Mims

Blood (2024) 144 (Supplement 1): 7929.

https://doi.org/10.1182/blood-2024-210135

Published: 2024

Journal Articles

Comparison of Two Myeloablative Total-Body Irradiation (MAC-TBI) Regimens: 1200 Cgy Vs 800 Cgy of TBI for Allogeneic Stem Cell Transplantation in Adults with Hematological Malignancies

Blood (2024) 144 (Supplement 1): 7303.

https://doi.org/10.1182/blood-2024-194146

Published: 2024

Journal Articles

GATA2 -Mutated AML: Clinical Outcomes and Spectrum of Infections in Patients Undergoing or Not Allogeneic Stem Cell Transplantation

Blood (2024) 144 (Supplement 1): 7309.

https://doi.org/10.1182/blood-2024-202650

Published: 2024

Journal Articles

Real-World Experience of Venetoclax Target Dosing with Concomitant Posaconazole in Adult Patients with Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2432.

https://doi.org/10.1182/blood-2024-203704

Published: 2024

Journal Articles

A Phase 1b/2 Trial of Liposomal Cytarabine and Daunorubicin (CPX-351) in Intermediate to High-Risk Acute Myeloid Leukemia for Patients Who Have Failed an Initial Cycle of Induction Chemotherapy

Blood (2023) 142 (Supplement 1): 5946.

https://doi.org/10.1182/blood-2023-184344

Published: 2023

Journal Articles

T Cell Dysfunction and Exhaustion in Patients with CLL: The Impact of Long Term Ibrutinib Treatment

Shanmugapriya Thangavadivel, Charlene Mao, Meixiao Long, Shrilekha Misra, Samon Benrashid, Britten Gordon, Alexander He, Tzung-Huei Lai, Kerry A Rogers, Seema A Bhat, Adam S Kittai, John C. Byrd, Jennifer A. Woyach

Blood (2023) 142 (Supplement 1): 4631.

https://doi.org/10.1182/blood-2023-189755

Published: 2023

Journal Articles

A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis

Blood (2022) 140 (Supplement 1): 9470–9472.

https://doi.org/10.1182/blood-2022-159586

Published: 2022

Journal Articles

The Multi-CDK Inhibitor Dinaciclib Shows Synergistic Activity with the BET Inhibitor PLX51107 and Reverses BET Resistance through Inhibition of Canonical Wnt Signaling in Acute Myeloid Leukemia (AML)

Blood (2022) 140 (Supplement 1): 3075–3076.

https://doi.org/10.1182/blood-2022-160277

Published: 2022

Journal Articles

Trial in Progress: Phase 1/2 Study Evaluating the Safety and Efficacy of Iov-2001, an Autologous, Non-Genetically Modified, Polyclonal T-Cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Javier Pinilla Ibarz, Meixiao Long, John Lister, Jennifer A. Woyach, Friedrich Graf Finckenstein, Madan Jagasia, Selda Samakoglu, Bhagyashree Yadav, Huiling Li, John C. Byrd

Blood (2021) 138 (Supplement 1): 3846.

https://doi.org/10.1182/blood-2021-145775

Published: 2021

Journal Articles

Effect of High Intensity Chemotherapy Vs Targeted Therapy on Survival in AML Patients Aged 60-75

Kieran D Sahasrabudhe, Melanie T Rebechi, Ying Huang, Greg K. Behbehani, Bhavana Bhatnagar, James S. Blachly, Bradley W Blaser, Uma Borate, Ramiro Garzon, Tamanna Haque, Karilyn Larkin, Meixiao Long, Alice S. Mims, Ayman Saad, Sumithira Vasu, Alison R. Walker, Sarah A Wall

Blood (2021) 138 (Supplement 1): 4125.

https://doi.org/10.1182/blood-2021-148676

Published: 2021

Journal Articles

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Peter Westervelt, MD PhD, Jorge E. Cortes, MD, Jessica K. Altman, Meixiao Long, MD, Vivian G. Oehler, MD, Ivana Gojo, MD, Jeanmarie Guenot, PhD, Patrick Chun, MD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 834.

https://doi.org/10.1182/blood-2019-129042

Published: 2019

Journal Articles

Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity

Meixiao Long, MD, Erich Williams, Clara Berard, Carolyn Cheney, BS, Eileen Hu, BS, Seema A. Bhat, MD, Kerry A. Rogers, MD, Jennifer Woyach, MD, Natarajan Muthusamy, DVM,PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 1049.

https://doi.org/10.1182/blood-2019-125417

Published: 2019

Journal Articles

Expansion and Characterization of Iovance Marrow Infiltrating Lymphocytes: A Potential Novel Therapeutic Strategy for the Treatment of Acute Myeloid Leukemia

Lavakumar Karyampudi, PhD, Ian Frank, Michelle Blaskovich, John C. Byrd, MD, Cecile Chartier, Meixiao Long, MD

Blood (2018) 132 (Supplement 1): 5683.

https://doi.org/10.1182/blood-2018-99-114825

Published: 2018

Journal Articles

Impact of Cytokine Release Syndrome on Outcomes after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation

Blood (2018) 132 (Supplement 1): 3357.

https://doi.org/10.1182/blood-2018-99-114100

Published: 2018

Journal Articles

γδ T cells for immunotherapy

Meixiao Long

Blood (2018) 132 (21): 2212–2213.

https://doi.org/10.1182/blood-2018-10-876078

Published: 2018

Journal Articles

Presence of a Translocation Is Associated with Short Time to Treatment from Diagnosis in IGHV Mutated Chronic Lymphocytic Leukemia (CLL) Patients

Nyla A. Heerema, PhD, Qiuhong Zhao, MS, Amy S. Ruppert, MAS, Heather Breidenbach, Jeffrey Jones, MD MPH, Leslie A. Andritsos, MD, Jennifer A. Woyach, MD, Farrukh T. Awan, Meixiao Long, MD PhD, Amber Gordon, MLS, Caitlin Coombes, BA, John C. Byrd, MD, Natarajan Muthusamy, DVM, PhD

Blood (2016) 128 (22): 4372.

https://doi.org/10.1182/blood.V128.22.4372.4372

Published: 2016

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Evaluation of cytarabine consolidation dosing in older adult patients with Acute Myeloid Leukemia

Toxicity of reduced dose versus standard dose pegaspargase in adolescents and young adults with acute lymphoblastic leukemia

Trial in progress: A Phase I/II study to investigate the combination of LP-118, ponatinib, vincristine and dexamethasone (LPVd regimen) in relapsed/refractory T-ALL/lbl

A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination with Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

Real World Outcomes of Patients (Pts) with Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) or Therapy-Related AML (t-AML) Receiving Venetoclax-Based Therapies

Comparison of Two Myeloablative Total-Body Irradiation (MAC-TBI) Regimens: 1200 Cgy Vs 800 Cgy of TBI for Allogeneic Stem Cell Transplantation in Adults with Hematological Malignancies

GATA2 -Mutated AML: Clinical Outcomes and Spectrum of Infections in Patients Undergoing or Not Allogeneic Stem Cell Transplantation

Real-World Experience of Venetoclax Target Dosing with Concomitant Posaconazole in Adult Patients with Acute Myeloid Leukemia

A Phase 1b/2 Trial of Liposomal Cytarabine and Daunorubicin (CPX-351) in Intermediate to High-Risk Acute Myeloid Leukemia for Patients Who Have Failed an Initial Cycle of Induction Chemotherapy

T Cell Dysfunction and Exhaustion in Patients with CLL: The Impact of Long Term Ibrutinib Treatment

A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis

The Multi-CDK Inhibitor Dinaciclib Shows Synergistic Activity with the BET Inhibitor PLX51107 and Reverses BET Resistance through Inhibition of Canonical Wnt Signaling in Acute Myeloid Leukemia (AML)

Trial in Progress: Phase 1/2 Study Evaluating the Safety and Efficacy of Iov-2001, an Autologous, Non-Genetically Modified, Polyclonal T-Cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Effect of High Intensity Chemotherapy Vs Targeted Therapy on Survival in AML Patients Aged 60-75

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity

Expansion and Characterization of Iovance Marrow Infiltrating Lymphocytes: A Potential Novel Therapeutic Strategy for the Treatment of Acute Myeloid Leukemia

Impact of Cytokine Release Syndrome on Outcomes after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation

γδ T cells for immunotherapy

Presence of a Translocation Is Associated with Short Time to Treatment from Diagnosis in IGHV Mutated Chronic Lymphocytic Leukemia (CLL) Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only